AbbVie stock slips as Q2 revenue rises 10.2 percent
Published on 09/09/2026 at 14:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AbbVie Inc. stock (US00287Y1091) closed at USD 248.75 on September 8, 2026, down 3.01 percent from the prior close, while the shares briefly traded at USD 252.40 in extended trading. The move came after the company said on July 31, 2026, that second-quarter revenue rose 10.2 percent year over year to USD 16.99 billion and earnings per share came in at USD 3.65, above the USD 3.61 consensus.
Q2 still sets the tone
According to MarketBeat, AbbVie also reported a Q2 2026 net margin of 9.80 percent and said the quarter a year earlier brought EPS of USD 2.97. That puts the latest quarter's EPS 22.9 percent above the prior-year period.
According to MarketBeat, AbbVie set Q3 2026 guidance at EPS of USD 3.84 to USD 3.88, a range that sits above the Q2 actual of USD 3.65. The same source says analysts now expect full-year 2026 EPS of USD 14.05.
Price and valuation
MarketBeat data showed AbbVie at a market capitalization of USD 439.49 billion, a 52-week range of USD 190.75 to USD 267.47 and a volume of 5.57 million shares on September 8, 2026. The consensus target price stood at USD 275.95, which is 10.9 percent above the close of USD 248.75.
What stands out
For investors, the current mix is straightforward: Q2 revenue rose 10.2 percent, EPS beat the estimate by USD 0.04, and the stock still traded 7.0 percent below the 52-week high of USD 267.47 on September 8, 2026. A first. AbbVie's dividend was also paid on August 14, 2026, after a quarterly payout of USD 1.73 per share and an annualized rate of USD 6.92.
AbbVie stock at a glance
- Company: AbbVie Inc.
- ISIN: US00287Y1091
- Ticker: ABBV
- Trading venue: NYSE
- Price (as of September 8, 2026, 3:59 PM): USD 248.75
- Market capitalization: USD 439.49 billion (as of September 8, 2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: S&P 500
